Clinical Trials on UGT1A1 Gene Mutation in Russian Federation

Total 20 results

N.N. Blokhin National Medical Research Center of...

Recruiting

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy (TRUST)

Non Small Cell Lung Cancer | EGFR Gene Mutation | T790M

Russian Federation
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

United States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Novosibirsk Scientific Research Institute for Circulatory...

Recruiting

The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting

Russian Federation
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
Blokhin's Russian Cancer Research Center

Unknown

Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) (EPITOC)

Ovarian Neoplasms | Ovarian Cancer | Chemotherapy | BRCA1 Mutation | BRCA2 Mutation | Serous Adenocarcinoma

Russian Federation
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
Artur Biktimirov

Enrolling by invitation

Study of Lower-limb Phantom Pain Syndrome Using Peripheral Nerve and Spinal Cord Stimulation

Amputation | Phantom Limb Pain | Lower Limb Amputation | Phantom Pain

Russian Federation
Artur Biktimirov

Enrolling by invitation

Study of Phantom Limb Pain Using Peripheral Nerve and Spinal Cord Stimulation

Amputation | Phantom Limb Pain | Phantom Pain

Russian Federation
MelanomaPRO, Russia
Crocus Medical B.V.

Completed

Advanced Melanoma in Russian Experience (ADMIRE)

BRAF V600 Mutation | Cutaneous Melanoma, Stage IV

Russian Federation
Genentech, Inc.

Completed

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Metastatic Melanoma, BRAF V600 Mutation Positive

Korea, Republic of, Russian Federation, Israel, United States
AstraZeneca

Completed

Asia Pacific and Russia Diagnostic Study for EGFR Testing (IGNITE)

EGFR Mutation Status in aNSCLC Patients

Korea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Astellas Pharma Inc

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

China, Malaysia, Russian Federation, Singapore, Thailand
AstraZeneca

Completed

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

HER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 Mutations

Italy, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain

Clinical Trials on UGT1A1 Gene Mutation in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations